A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy
and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell
Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University